Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
1. Royalty Pharma invests $300M for obexelimab development and commercialization. 2. Obexelimab targets IgG4-Related Disease, a significant unmet medical need. 3. Phase 3 trial results expected by year-end could influence FDA approval. 4. Obexelimab's launch projected in early 2027, pending regulatory approval. 5. Royalty Pharma receives 5.5% royalty on worldwide obexelimab sales.